Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Redmond

Showing results (191-200 of 205) with videos related to

Pageof 21
Sort By:
NPJ Breast Cancer|March 18, 2026
Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancerAlan Su, Erin C Hong, Nicole Moxon, et al.
Gut|July 22, 2020
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learningKorsuk Sirinukunwattana, Enric Domingo, Susan D Richman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast CancerDavid B Page, Joanna Pucilowska, Katherine G Sanchez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2022
Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical DataNatalie C Fisher, Ryan M Byrne, Holly Leslie, et al.
NPJ Breast Cancer|June 21, 2023
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancerDavid B Page, Joanna Pucilowska, Brie Chun, et al.
The Lancet. Oncology|August 11, 2022
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trialTomoko Yamazaki, Andrew J Gunderson, Miranda Gilchrist, et al.
The Lancet. Oncology|April 10, 2018
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trialJohn M Wrangle, Vamsidhar Velcheti, Manish R Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2020
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal CancerSudhir B Malla, David J Fisher, Enric Domingo, et al.
Gut|April 28, 2022
Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancerShania M Corry, Amy Mb McCorry, Tamsin Rm Lannagan, et al.
Nature Communications|December 8, 2022
Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive featuresDustin J Flanagan, Raheleh Amirkhah, David F Vincent, et al.
Pageof 21

Showing results (191-200 of 205) with videos related to

Sort By:
Pageof 21
NPJ Breast Cancer|March 18, 2026
Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancerAlan Su, Erin C Hong, Nicole Moxon, et al.
Gut|July 22, 2020
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learningKorsuk Sirinukunwattana, Enric Domingo, Susan D Richman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast CancerDavid B Page, Joanna Pucilowska, Katherine G Sanchez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2022
Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical DataNatalie C Fisher, Ryan M Byrne, Holly Leslie, et al.
NPJ Breast Cancer|June 21, 2023
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancerDavid B Page, Joanna Pucilowska, Brie Chun, et al.
The Lancet. Oncology|August 11, 2022
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trialTomoko Yamazaki, Andrew J Gunderson, Miranda Gilchrist, et al.
The Lancet. Oncology|April 10, 2018
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trialJohn M Wrangle, Vamsidhar Velcheti, Manish R Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2020
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal CancerSudhir B Malla, David J Fisher, Enric Domingo, et al.
Gut|April 28, 2022
Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancerShania M Corry, Amy Mb McCorry, Tamsin Rm Lannagan, et al.
Nature Communications|December 8, 2022
Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive featuresDustin J Flanagan, Raheleh Amirkhah, David F Vincent, et al.
Pageof 21